Egalet Corp. (NASDAQ:EGLT) insider Robert S. Radie sold 15,000 shares of the company’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $7.47, for a total transaction of $112,050.00. Following the completion of the transaction, the insider now owns 234,900 shares in the company, valued at $1,754,703. The sale was disclosed in a filing with the SEC, which is available through this link.

Shares of Egalet Corp. (NASDAQ:EGLT) opened at 7.64 on Wednesday. The stock has a 50 day moving average of $7.54 and a 200 day moving average of $6.58. Egalet Corp. has a 12 month low of $4.34 and a 12 month high of $11.96. The stock’s market cap is $187.51 million.

Egalet Corp. (NASDAQ:EGLT) last posted its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported ($0.97) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by $0.15. The business earned $3.45 million during the quarter, compared to analysts’ expectations of $3.83 million. Egalet Corp. had a negative return on equity of 86.03% and a negative net margin of 244.57%. The business’s quarterly revenue was up 259.4% on a year-over-year basis. During the same period in the prior year, the business posted ($1.03) earnings per share. On average, equities analysts anticipate that Egalet Corp. will post ($3.48) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Egalet Corp. (NASDAQ:EGLT)

A number of institutional investors have recently modified their holdings of the company. Janney Montgomery Scott LLC increased its position in shares of Egalet Corp. by 2.7% in the second quarter. Janney Montgomery Scott LLC now owns 55,754 shares of the specialty pharmaceutical company’s stock worth $614,000 after buying an additional 1,476 shares during the period. HighTower Advisors LLC increased its position in shares of Egalet Corp. by 8.8% in the second quarter. HighTower Advisors LLC now owns 229,664 shares of the specialty pharmaceutical company’s stock worth $1,140,000 after buying an additional 18,616 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of Egalet Corp. by 139.9% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 240,175 shares of the specialty pharmaceutical company’s stock worth $1,191,000 after buying an additional 140,046 shares during the period. BlackRock Fund Advisors increased its position in shares of Egalet Corp. by 154.5% in the second quarter. BlackRock Fund Advisors now owns 899,471 shares of the specialty pharmaceutical company’s stock worth $4,461,000 after buying an additional 546,034 shares during the period. Finally, BlackRock Investment Management LLC increased its position in shares of Egalet Corp. by 3,736.2% in the second quarter. BlackRock Investment Management LLC now owns 84,128 shares of the specialty pharmaceutical company’s stock worth $417,000 after buying an additional 81,935 shares during the period. 67.18% of the stock is currently owned by institutional investors.

A number of equities analysts have commented on EGLT shares. Cantor Fitzgerald restated a “buy” rating and issued a $21.00 target price on shares of Egalet Corp. in a research note on Thursday, September 8th. Gabelli began coverage on shares of Egalet Corp. in a research report on Tuesday, September 13th. They issued a “buy” rating and a $9.50 price target for the company. Finally, Zacks Investment Research cut shares of Egalet Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday, August 9th.

Egalet Corp. Company Profile

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.

5 Day Chart for NASDAQ:EGLT

Receive News & Stock Ratings for Egalet Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet Corp. and related stocks with our FREE daily email newsletter.